Serological antibodies and surgery in a population-based inception cohort of Crohn’s disease patients – the IBSEN study

References

• Frolkis AD, Dykeman J, Negron ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996–1006.
   PubMed Web of Science ®Google Scholar
• Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5(12):1430–1438.
   PubMed Web of Science ®Google Scholar
• Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(8):1–10.
   Web of Science ®Google Scholar
• Prideaux L, De Cruz P, Ng SC, et al. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2012;18(7):1340–1355.
   PubMed Web of Science ®Google Scholar
• Benor S, Russell GH, Silver M, et al. Shortcomings of the inflammatory bowel disease Serology 7 panel. Pediatrics. 2010;125(6):1230–1236.
   PubMed Web of Science ®Google Scholar
• Aitola P, Miettinen A, Mattila A, et al. Effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with chronic ulcerative colitis. J Clin Pathol. 1995;48(7):645–647.
   PubMed Web of Science ®Google Scholar
• Smids C, Horjus Talabur Horje CS, Groenen MJM, et al. The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient. Scand J Gastroenterol. 2017;52(10):1104–1112.
   PubMed Web of Science ®Google Scholar
• Kovacs G, Sipeki N, Suga B, et al. Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients. PLoS One. 2018;13(3):e0194166.
   PubMed Web of Science ®Google Scholar
• Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144–164.
   PubMed Web of Science ®Google Scholar
• Moum B, Vatn MH, Ekbom A, et al. Incidence of inflammatory bowel disease in southeastern Norway: evaluation of methods after 1 year of registration. Southeastern Norway IBD Study Group of Gastroenterologists. Digestion. 1995;56(5):377–381.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Targan SR, Dubinsky MC, et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn’s disease behavior. Inflamm Bowel Dis. 2011;17(12):2488–2496.
   PubMed Web of Science ®Google Scholar
• Olbjorn C, Cvancarova Smastuen M, Thiis-Evensen E, et al. Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy. Scand J Gastroenterol. 2017;52(4):414–419.
   PubMed Web of Science ®Google Scholar
• Ossum AM, Palm O, Lunder AK, et al. Ankylosing spondylitis and axial spondyloarthritis in patients with long-term inflammatory bowel disease: results from 20 years of follow-up in the IBSEN Study. J Crohns Colitis. 2018;12(1):96–104.
   PubMed Web of Science ®Google Scholar
• Arora U, Kedia S, Garg P, et al. Colonic Crohn’s disease is associated with less aggressive disease course than ileal or ileocolonic disease. Dig Dis Sci. 2018;63(6):1592–1599.
   PubMed Web of Science ®Google Scholar
• Arieira C, Curdia Goncaves T, Dias de Castro F, et al. Clinical course in Crohn’s disease: factors associated with behaviour change and surgery. Scand J Gastroenterol. 2018;53(10–11):1222–1227.
   PubMed Web of Science ®Google Scholar
• Solberg IC, Lygren I, Cvancarova M, et al. Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(3):406–414.
   PubMed Web of Science ®Google Scholar
• Thia KT Jr., Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010;139(4):1147–1155.
   PubMed Web of Science ®Google Scholar
• Kohoutova D, Drahosova M, Moravkova P, et al. Anti-outer membrane protein C and anti-glycoprotein 2 antibodies in inflammatory bowel disease and their association with complicated forms of Crohn’s disease. BMC Gastroenterol. 2014;14:190.
   PubMed Web of Science ®Google Scholar
• O’Donnell S, O’Sullivan M, O’Morain CA, et al. The clinical significance of antimicrobial serologic responses within an Irish Crohn’s disease population. Eur J Gastroenterol Hepatol. 2013;25(12):1464–1469.
   PubMed Web of Science ®Google Scholar
• Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004;99(12):2376–2384.
   PubMed Web of Science ®Google Scholar
• Lawrance IC, Murray K, Hall A, et al. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients. Am J Gastroenterol. 2004;99(11):2186–2194.
   PubMed Web of Science ®Google Scholar
• Zhou F, Xia B, Wang F, et al. The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China. Clin Chim Acta. 2010;411(19–20):1461–1465.
   PubMed Web of Science ®Google Scholar
• Papp M, Altorjay I, Dotan N, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008;103(3):665–681.
   PubMed Web of Science ®Google Scholar
• Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn’s disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002;123(3):689–699.
   PubMed Web of Science ®Google Scholar
• Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology. 2005;128(7):2020–2028.
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998;115(4):822–829.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Peeters M, Vlietinck R, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis. 2001;7(1):8–15.
   PubMed Web of Science ®Google Scholar
• Billiet T, Papamichael K, de Bruyn M, et al. A matrix-based model predicts primary response to infliximab in Crohn’s disease. J Crohns Colitis. 2015;9(12):1120–1126.
   PubMed Web of Science ®Google Scholar
• Riis L, Vind I, Vermeire S, et al. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm Bowel Dis. 2007;13(1):24–32.
   PubMed Web of Science ®Google Scholar
• Kevans D, Tyler AD, Holm K, et al. Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis. J Crohns Colitis. 2016;10(3):330–337.
   PubMed Web of Science ®Google Scholar
• Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222–227.
   PubMed Web of Science ®Google Scholar